This study assessed the ability of three adjuvants (aluminum hydroxide, Essai (microparticle) and Phema (nanoparticle)) to enhance the immune response of chickens to an H6N2 avian influenza DNA vaccine. No hemagglutination inhibition (HI) antibody was detected following two intramuscular immunizations with the adjuvanted and non-adjuvanted pCAG-HAk vaccine, which has previously been shown to induce moderate H6 HA antibody response in SPF chickens. Following virus challenge, neither the vaccinated group without adjuvant nor the Essai adjuvanted group showed a statistically significant reduction in virus shedding in oropharyngeal and cloacal swabs compared with the naïve control group. However, the aluminum hydroxide and Phema adjuvanted groups significantly reduced the frequency of virus shedding in oropharyngeal swabs, indicating that these adjuvants appeared to further enhance the vaccine potency. Aluminum hydroxide holds promise as an adjuvant for enhancing DNA-induced immune response in chickens owing to its low price and safety record.
Introduction
Since the initial report on DNA vaccine technology in 1993, DNA vaccines have been shown to protect a number of animal species against various pathogens (viruses, bacteria and parasites), cancer, autoimmune diseases and allergies .
In comparison with traditional inactivated or live attenuated whole microorganism vaccines, DNA vaccines (plasmid DNA) have some remarkable features, e.g. stability of the plasmid DNA, speed and simplicity of vaccine production, and the ability to produce the vaccine for highly virulent organisms in a safe manner (Suarez and Schultz-Cherry, 2000; Smith et al., 2010) . Immunization via multiple routes with plasmid DNA can elicit humoral and cell-mediated immune responses, but their poor immunogenicity hinders their commercial development.
As adjuvants have historically played a major role in successful vaccine development (Scheerlinck et al., 2006) , a range of chemical adjuvants have been examined in an attempt to improve plasmid DNA immunogenicity. Conventional adjuvants, many of which are very effective for inactivated and subunit vaccines, have either not been tested with DNA vaccines or have not been shown to be beneficial in the mouse model (van Drunen Littel-van den Hurk et al., 2004) . A variety of microparticles and nanoparticles have shown promise for enhancing cellular and humoral immune responses (Cui and Mumper, 2003a; O'Hagan et al., 2004; Li et al., 2009; Jazayeri et al., 2012) . Thus, further investigation of conventional or novel adjuvants and their formulation technologies might improve the utility of plasmid DNA vaccination.
Aluminium salts, referred to as alum, including aluminium phosphate, aluminium hydroxide and other aluminium-containing salts, have been characterized and are commonly used as conventional adjuvants to increase humoral immune responses (Ulmer et al., 2000) . They are currently licensed for human and animal use (Gupta, 1998) ; however, their potential as DNA vaccine adjuvants has had limited Downloaded by [Murdoch University Library] at 00:35 04 July 2016 investigation (Ulmer et al., 2000) . Alum-DNA formulations increased the capacity of some DNA vaccines to induce antibody responses up to 100-fold in mice and guinea pigs, and 5-10-fold in non-human primates (Gupta, 1998) .
The development of additional adjuvants has been driven principally by the shortcomings of existing adjuvants. Various particulate carriers e.g. microparticles, emulsions, immune stimulating complexes, liposomes, virosomes and virus-like particles have been investigated as vaccine delivery systems (O'Hagan et al., 2006) . Among these, microparticle-based technologies have gained considerable interest for use with vaccines. In particular, the copolymer poly-DL-lactic-co-glycolic acid (PLGA) has been extensively investigated as a carrier for plasmid DNA immunogens (Cui and Mumper, 2003a) . The antibody response induced by plasmid DNA-coated Poly-lactide-co-glycolide (PLG) -cetyltrimethyl ammonium bromide (CTAB) (PLG-CTAB) micro-particles in mice was markedly enhanced by the addition of aluminium phosphate (Singa et al., 2000) . PLG delivery of HIV DNA vaccines was shown to be effective at inducing antibody and cell-mediated immune responses in various species, including rhesus macaques (O'Hagan et al., 2004) . The microparticle-formulated plasmid DNA encoding the NP gene of A/PR/8/34 (H1N1) virus was shown to enhance immune response in mice (Hartikka et al., 2008 (Scheerlinck et al., 2006) , pigs and cattle (Aucouturier et al., 2001) . Also, a cationic nanoparticle formulated plasmid DNA encoding a reporter gene enhanced in vitro cell transfection efficiency and produced 16-200-fold greater immune responses in mice than naked plasmid DNA alone following multiple delivery routes.
Co-administration of cholera toxin and lipid A with a nanoparticle-based plasmid DNA showed a synergistic effect and hence further enhanced immune responses (Cui & Mumper, 2003b) . Recently, nanoparticles have been used as adjuvants for enhancing the immunogenicity of protein-based influenza vaccines in mice (Petukhova et al 2013; Neuhaus et al., 2014; Ross et al., 2014; Russell et al., 2016) and chickens (Asl Najjari et al., 2015; Khalili et al., 2015) . Sliver nanoparticles with polyethylene glycol were also used to formulate plasmid DNA encoding H5N1 influenza virus hemagglutinin (HA) gene to assess humoral and cellular immune responses in chickens (Jazayeri, et al., 2012) . Thus, nanoparticles, as a novel class of adjuvants, have the potential to induce immune responses to protein or plasmid DNA immunogens without the side effects typically associated with local tissue damage caused by conventional chemical adjuvants. there have been no reports on nanoparticle-based avian influenza DNA vaccines in chickens.
In a previous experiment (Shan et al., 2016) , the chemical adjuvant lipofectin showed some enhancement of an avian influenza HA DNA-induced immune response in chickens in terms of increasing the seroconversion rate of vaccinated birds and the level of antibody production, and reducing virus shedding in both oropharyngeal and cloacal swabs. However, it is prohibitively expensive for routine use in poultry. Thus, an experimental adjuvant for DNA vaccination (Montanide™ Essai 849101) from Seppic (Paris, France), a new, self-prepared nanoparticle (Phema), and two variations of conventional alum were investigated as adjuvants for a plasmid DNA vaccine (pCAG-HAk) (Shan et al., 2011) against a low pathogenicity avian influenza virus in chickens and the results are reported and discussed here.
Materials and Methods
Plasmid DNA used for the vaccine. The pCAG-HAk plasmid DNA expressing the complete haemagglutinin (HA) gene of avian influenza A/Eurasian coot/Western Australia/2727/1979 (H6N2) virus, together with a Kozak sequence, in a pCAGGS vector, was used as a DNA vaccine as described previously (Shan et al., 2011) . The optimized DNA dose had been determined previously for this plasmid and for four other expression vectors (Shan et al., 2011; Shan et al., 2016) . Preparation of DNA-coated alum. Aluminum hydroxide (Al (OH)3) gel was prepared from aluminum potassium sulphate dodecahydrate (AlK(SO4)2.12H2O) (BDH Chemicals Ltd, Australia) as described by Scheerlinck et al. (2006) . Briefly, 10 mL of 10% aluminium potassium sulphate was added drop-wise to 22.8 mL of 0.25N NaOH to prepare alum gel. Two versions of the alum adjuvant gels were prepared depending on the buffers used: 0.9% NaCl (referred to as alum-NaCl) and PBS (pH 7.2) (referred to as alum-PBS). 1mL of the 400 µg/µL alum suspension was then mixed with equal volumes of either 0.9% NaCl or PBS solutions containing 0.2 mL plasmid DNA (9.3 µg/µL) respectively. To obtain the optimal DNA-binding to the alum adjuvants, different concentrations of alum (400, 200, 100, 50 µg/µL), different diluting buffers (PBS or 0.9% NaCl), different binding times (0.5, 1, 3, 5, 8, 27 hr) and different temperatures (4°C and 22°C) were used to prepare the adjuvants, using a constant concentration of plasmid DNA (2.4 µg/μL). The emulsions were finally diluted to a concentration of 0.5 µg/µL DNA in their respective solutions for immunization.
Formulation of plasmid DNA vaccines with adjuvants
Preparation of DNA-coated Essai. The adjuvant referred to as Essai was a ready-touse Montanide™ type vaccine adjuvant (and designated Essai 849101), provided by the Seppic company in France for an initial trial. It was provided with instructions for preparation but no details of the ingredients. Formulation of the plasmid DNA using Essai 849101 was carried out according to the manufacturer's instructions. Briefly, DNA was diluted in PBS (pH 7.2) and then Essai 849101 was added dropwise with gentle stirring to the DNA preparation to give final concentrations of 0.5 µg/µL for DNA and 10% (v/v) for Essai 849101. Following initial mixing, the mixture was stirred for a further 10 min at room temperature.
Preparation of the DNA-conjugated nano-beads. A novel polymer (2-hydroxyethyl-methacrylate) (Phema), which formed a 150-300 nm hydrophilic nanoparticle suspension, was provided by the Nanotechnology Group, Murdoch University. Optimization of the solvent for mixing the Phema and DNA was determined using 100% dH2O, dH2O/ethanol (50:50) and 100% ethanol and the level of DNA binding was determined by measurement of free DNA in the suspension as described below. Consequently, 2 mL of 1% Phema (w/v in ethanol) was sonicated for a few seconds on ice, followed by the addition of 1 mL of 1% polyvinyl alcohol (PVA) (w/v in dH2O). The mixture was sonicated for 1 min on ice and 200 µL of plasmid DNA (9.3 µg/µL) was subsequently added. After sonication for 2 min on ice, the resultant solution was filtered through a 0.2 µm membrane to remove the surfactant. The flow-through was centrifuged at 15,000 g for 20 min at room temperature and the pellet was dissolved in PBS. The amount of DNA present was calculated by subtracting the amount of DNA in the supernatant, measured by a Nanodrop spectrophotometer (Thermo Scientific, MA, USA), from the total DNA added. and orally (0.3 mL). Following challenge, the chickens were clinically examined daily and oropharyngeal and cloacal swabs were collected every second day over a seven day period. Virus isolation was performed as described previously (Shan et al., 2010) .
Vaccination regime used in chickens.
Statistical analysis. Statistical analyses of experimental data were conducted using the paired-sample T-test, and one way analysis of variance (ANOVA) using SPSS statistical software version 15 as well as Chi-square (Fisher's exact test was used when the sample number was less than 5) using Statistix. Statistical significance was defined at the level of p<0.05.
Results
Optimization of DNA vaccine adjuvant formulations. As shown in Tables 1 and 2, the DNA binding rate increased with the increase of alum-NaCl concentration. DNA binding with alum-NaCl occurred within the first 1 h. Temperature did not affect the DNA binding rate after 3 h. The 400 µg/µL alum-NaCl absorbed nearly 100% of plasmid DNA either at room temperature or 4°C by 1 h after mixing. Thus, 400 µg/µL alum-NaCl and binding for 2 h at room temperature was used for the formulation of the DNA vaccine. In contrast, alum-PBS did not bind plasmid DNA even after overnight incubation.
As shown in Figure 1 , the Phema particles in the presence of plasmid DNA were found to be uniform in size, with the majority of the particles being about 300 nm in diameter. Experiments with different ratios of alcohol and water showed that Phema adjuvant prepared with 100% ethanol as solvent gave the highest DNA binding rate.
Thus, 100% alcohol was used for the preparation of the Phema adjuvant vaccine.
Subsequently, the maximal plasmid DNA-Phema binding rate, determined using a Effect of adjuvants on antibody response. No HI titre was detected in any Hy-Line chickens three weeks after the first or second vaccination. By 10 days post virus challenge, all birds sero-converted with a range of HI titres as shown in Table 3 .
There was a statistically significant difference (P<0.05) in the geometric mean titre (GMT) of HI antibody between pre-and post-challenge in all vaccinated groups and the naïve control group using the paired-sample T test.
There was no significant difference (ANOVA, P>0.5) in HI antibody GMT post-challenge between the naïve control group and any of the vaccinated groups, nor was there any significant difference (ANOVA, P>0.5) between the pCAG-HAk group and any of six pCAG-HAk adjuvanted groups.
Effect of adjuvants on virus shedding. As shown in Table 4 , in comparison with the naïve control group, the pCAG-HAk vaccinated group reduced the virus excretion rate from 70.8% to 45% in oropharyngeal swabs post-challenge and from 12.5% to 0 in cloacal swabs. However, the pCAG-HAk vaccinated group was not significantly different from the naïve control group in oropharyngeal and cloacal swabs.
In comparison with the naïve control group, the alum-NaCl adjuvanted pCAG-HAk group showed a reduction in virus shedding rate from 70.8% to 40% in oropharyngeal swabs post challenge and showed no virus shedding in cloacal swabs. There was a significant difference (Chi square, P= 0.04) for oropharyngeal swabs between the naïve control group and the alum-NaCl adjuvanted pCAG-HAk group. The alum-PBS adjuvanted pCAG-HAk group was also significantly (Chi square, P= 0.018) different from the naïve control group in frequency of virus shedding in oropharyngeal swabs.
However, there was no significant difference in virus shedding in oropharyngeal and cloacal swabs between the pCAG-HAk vaccinated and either the alum-NaCl or alum-PBS adjuvanted groups. Neither was there a significant difference between the alum-NaCl and alum-PBS groups.
Although the Essai adjuvanted pCAG-HAk group showed less virus shedding in both oropharyngeal and cloacal swabs than the naïve control group, there was no significant difference between them. Neither was there a significant difference between the pCAG-HAk and the Essai adjuvanted groups.
There was a significant difference (Fisher's exact test, P=0.014) between the naïve control group and the 100µg Phema adjuvanted pCAG-HAk group in the rate of virus shedding in oropharyngeal swabs but no significant difference in cloacal swabs.
However, the 200µg or 10 µg Phema adjuvanted pCAG-HAk groups was not significantly different in virus shedding from the naïve control group. Furthermore, there was no significant difference in virus shedding between the pCAG-HAk group and the 200µg, 100 µg or 10 µg Phema adjuvanted groups.
Discussion
The first DNA vaccine that was studied in poultry in 1993 was directed against avian influenza virus . Thereafter DNA vaccination against avian influenza has been widely studied in chickens, but their capacity to induce antibody responses has been shown to be variable in chickens (Kodihalli et al., 1997; Suarez & Schultz-Cherry, 2000; Le Gall-Recule, et al., 2007; Shan et al., 2011; Jazayeri, et al., 2012; Ogunremi, et al., 2013; Meunier, et al., 2016; Shan et al., 2016) . Moreover, promising results have been mainly obtained in SPF birds (Meunier, et al., 2016) . In our previous report, the pCAG-HAk vaccine induced moderate antibody responses in SPF chickens (Shan et al., 2011) , however, the same DNA vaccine did not induce measurable antibody in Hy-Line chickens (Shan et al., 2011) . Furthermore, we found that even if other serological methods such as ELISA or western blot were used, no or very weak antibody responses were detected in the evaluation of the VR10102 vector vaccine expressing the same HA gene of H6N2 AIV (Shan et al., 2016) . The reason for this is unknown but worth further investigation. However, this unexpected result increased high difficulty in the evaluation of developed adjuvants in the present study.
DNA vaccines appear to act as their own adjuvant owing to the presence of immune stimulatory DNA sequences in their backbone (Davis et al., 1997) , and can be effective without adjuvants. However, incorporation of either chemical or genetic adjuvants to DNA vaccines modulates or enhances their efficacy (Cui & Mumper, 2003a) . As our previous study demonstrated, lipofectin (liposome) was able to generate an enhanced DNA-induced immune response (Shan et al., 2016) . In the present study, aluminum hydroxide (traditional adjuvant), Essai (microparticle) and Phema (nanoparticle) were assessed to see if the humoral immune response could be enhanced.
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Although the groups administered the adjuvanted vaccine were not statistically different in virus shedding in oropharyngeal and cloacal swabs from the pCAG-HAk group, both alum groups and the 100 µg Phema group showed significant reduction in virus shedding in the oropharynx compared with the naïve control group. This indicated that alum and Phema adjuvants appeared to further augment the immune response induced by the pCAG-HAk vaccine. However, Essai did not show any effect.
In an H5 avian influenza DNA vaccine study comparing adjuvants, two different cationic liposomes (lipofectin and lipotaxi) improved antibody titres, whereas chemical adjuvants (including 25% sucrose, diethylaminoethyl dextran, calcium phosphate and polybrene) decreased the antibody response in chickens (Suarez & Schultz-Cherry, 2000) . Another study showed that formulation with cationic polymer polyethyleneimine decreased the immune responses generated by intramuscularly administered plasmid DNA encoding diphtheria toxin (Anderson et al., 2004) .
Administration of nano-encapsulated avian influenza virus H5 DNA vaccine induced both the antibody and cell-mediated immune responses in chickens (Jazayeri, et al 2012) . These studies all illustrate that chemical adjuvants for DNA vaccines were not always effectivebut highlight the need for further investigation.
Immunization of chickens with the plasmid DNA expressing the H5 influenza virus hemagglutinin by gene gun did not produce detectable pre-challenge antibodies, but produced high antibody titres after challenge, and the vaccine provided complete protection after homologous virus challenge (Kodihalli et al., 1997) . Similar results with poor antibody responses, but protection from challenge, have been reported in other studies with influenza viruses in mice or chickens (Fynan et al., 1993; Robinson et al., 1993) . Our results showed similarities with these studies. The pCAG-HAk vaccine did not induce measurable antibody before challenge in Hy-Line chickens, but showed a reduction in oropharyngeal shedding and absence of cloacal shedding after challenge. Although the cellular immune response was not measured in chickens in this study, evidence of protection after DNA vaccination in the absence of humoral immunity is considered an indicator of cellular immunity. In this regard, one can speculate that either alum or Phema stimulated cellular immune responses to some degree.
Aluminum hydroxide has a net positive charge in 0.9% NaCl (pH 7.0) and hence alum-NaCl binds to the negatively charged plasmid DNA. Aluminum hydroxide in PBS possibly reacted to produce aluminum phosphate, which would have conferred a net negative charge to the surface of alum and prevented binding to DNA. This explains why alum-NaCl binds DNA and alum-PBS does not. Ulmer et al. (2000) reported that non-DNA-binding aluminum salts (DNA-aluminum phosphate formulations) significantly enhanced antibody titres in mice, guinea pigs and Rhesus monkeys compared with naked DNA. In contrast, DNA/aluminum hydroxide formulations (DNA binding aluminum salt) were less potent than naked DNA. Our results showed that both DNA-binding (alum-NaCl) and non-DNA-binding (alum-PBS) aluminum-based adjuvants enhanced immune responses initiated by the pCAG-HAk DNA vaccine in terms of frequency of virus shedding in the oropharynx, although there was no significant difference between these two groups. Direct comparison of the effect of these adjuvants on antibody responses could not be carried out due to the Hy-Line chickens not producing antibody responses to the pCAG-HAk vaccines.
Aluminum compounds are currently the most commonly used adjuvants for protein vaccines due to their good safety record and low cost. However, their exact mechanisms of action are not yet fully understood. They may act via several mechanisms. Aluminum compounds precipitate protein antigens to form a "depot" at the site of injection, which allows for a slow release of antigen (Gupta, 1998) .
Presumably this may be the case for a DNA/alum-NaCl formulation but the depot effect would not apply for the non-binding DNA/alum-PBS adjuvant.
Recent findings showed that the immunostimulatory properties of alum may be expressed by activating the NLRP3 inflammasome in myeloid cells as part of the inate immune system. The NLRP3 inflammasome leads to caspase-1 activation and subsequent processing of IL-1b and IL-18 into their biologically active forms (Spreafico et al., 2010; Oleszycka and Lavelle, 2014) . Alum also induces Syk and/or PI3 kinase signaling, resulting in promoting PGE2 secretion in macrophages, and inhibition of IL-12p70 in dendritic cells. This leads to induction of Th2 immune responses in preference to Th1 responses (Flach et al., 2011) .
Nevertheless, DNA containing CpG motifs are one of the most potent cellular adjuvants and act via activation of a Toll receptor pathway (Weiner et al., 1997) .
Presumably, alum showed enhanced immune response induced by the pCAG-HAk vaccine through the NLRP3 inflammasome and PI3-Syk kinase signalling pathways or by other unidentified mechanisms. This needs to be further investigated.
The use of particulate carriers as novel vaccine delivery systems is an area currently receiving a high level of interest. Micro-and nano-size particle characteristics, such as size and surface properties, including surface charge and hydrophobicity, affect vaccine efficacy (Xiang et al., 2006) . Some studies on DNA vaccines have shown that nanoparticles might be more successful in stimulating immune responses in vivo than microparticles (Singh et al., 2000; O'Hagan, 2004) . The current study with a DNA vaccine in chickens lends support to this. A range of inert nanoparticles have been tested and shown to be effective delivery vehicles for protein and peptide antigens.
Nevertheless, application of nanoparticles with DNA vaccines is still at the exploratory stage (Cui & Mumper, 2003b; Minigo et al., 2007) . A biodegradable copolymer Phema has been used in a drug delivery system (Piotrowicz et al., 2006) .
However, there appears to be no previous reports using Phema as an adjuvant.
Due to the hydrophilicity of Phema, it is suspected that the ethanol solvent used in the current study may have imparted positive surface charges and allowed more absorption of the plasmid DNA than with water as a solvent. Plasmid DNA was possibly absorbed to the surface of Phema through electrostatic interaction or covalent OS and CS refer to oropharyngeal and cloacal swabs respectively. For the OS row, different uppercase superscript letters indicate statistical differences (P < 0.05) within the row using Chi square or Fisher's exact test. There were no significant differences between groups for the CS. Downloaded by [Murdoch University Library] at 00:35 04 July 2016
